Bay Area Therapy Center Expand Treatment Options Offering Comprehensive Mental Health Services in San Francisco ...

About duvakitug Duvakitug is a potential best-in-class human IgG1-λ2 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15 ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

" Nous ne vivons plus plus longtemps ", conclut cette équipe d’épidémiologistes de l’Université d'East Anglia (UEA, Angleterre). L’analyse, publiée dans le Lancet Public Health, révèle en effet un ral ...

renforcer la compétitivité et la capacité de production des médicaments essentiels en Europe grâce à des mécanismes de ...

LONDON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage clinical company developing lifesaving treatments for advanced liver diseases, announced today the appointment of a series of ...

Title: Impact of the Enzyme Replacement Therapy, INZ-701, in Children with ENPP1 Deficiency: Experience from an Expanded Access Program Presentation Number: 10 – Poster Session Date: Saturday, ...

The proceeds from the exercise of the warrants will be used for general working capital purposes, including Firefly’s recently announced strategic initiative to build the world’s first foundation ...

CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference ...

Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced the ...

WEST VALLEY CITY, Utah, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company committed to bringing supply stability and innovation to radioisotope markets, was named “Researcher of the Year” at ...

Ivor Elrifi, CEO of Tiziana Life Sciences, commented, “Partnering with Renaissance is a significant milestone in our mission to bring intranasal foralumab to patients in need. Their proven track ...